欲获取完整数据与信息，请访问Home – Investor Day (q4ir.com)，查看强生于2023年12月5日发布的报告。
[1] Non-GAAP measure; excludes the impact of translational currency.
[2] Excluding COVID-19 Vaccine.
[3] Non-GAAP financial measure; excludes the impact of translational currency, intangible amortization expense and special items;
[4] Based on risk-adjusted sales projections.
[5] Market Size and Weighted Average Market Growth Rate（WAMGR）reflect the following sources: internal estimates, Fitch, HRI, GlobalData, and DRG
[6] Products launched within the last five years
[7] 2025-2030 CAGR based on risk-adjusted operational sales projections
[8] Peak year non-risk-adjusted operational sales, including partner sales
[9] Risk-adjusted basis including current-year approvals
[10] 代表2018-2022年期间数据
关于前瞻性陈述的注意事项：
This presentation contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies; the Company’s ability to realize the anticipated benefits from the separation of the Company’s Consumer Health business; and the New Consumer Health Company’s ability to succeed as a standalone publicly traded company.
A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 1, 2023, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this presentation speaks only as of the date of this presentation. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
关于非GAAP财务指标的注意是事项；
The slides contained in this presentation refer to certain non-GAAP financial measures including operational sales1, adjusted operational earnings per share2, non-risk adjusted3 operational sales, risk adjusted3 operational sales, free cash flows, operational sales1 CAGR. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.
A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures in our historical financial statements can be found on the Investor Relations section of our website.
